ArticleAntimicrobial agents and chemotherapy2004
In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- Association between point mutations of macrolide-resistantFrontiers in pharmacology · 2025Pooled it
- Epidemiological Characteristics and Clinical Impact of Macrolide-Resistant Mycoplasma pneumoniae Infection in Children in Southwest China, 2021-2025.The clinical respiratory journal · 2026Article
- Reporting macrolide-resistantJournal of clinical microbiology · 2026Review
- Antimicrobial Susceptibility and Distribution Characteristics ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Clinical performance of two commercial PCR assays for the detection of macrolide resistance inJournal of clinical microbiology · 2026Article
- Collateral effects of antibiotic resistance in Campylobacter jejuni.FEMS microbiology letters · 2026Article
- Macrolide-resistantFrontiers in pediatrics · 2026Article
- Novel features ofMicrobial genomics · 2026Article
- Whole genome sequencing confirmed theASM case reports · 2025Article
- A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro.The Journal of antimicrobial chemotherapy · 2025Article
- Recent Macrolide Resistance Pattern of Mycoplasma Pneumonia in the World: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2025Review
- Macrolide resistance inFrontiers in cellular and infection microbiology · 2025Article
- Prevalence ofOpen forum infectious diseases · 2024Article
- Novel Knowledge of Macrolide Resistance inMicroorganisms · 2024Article
- A Novel Detection Procedure for Mutations in the 23S rRNA Gene of Macrolide-ResistantMicroorganisms · 2023Article
- Performance of the first commercial dual resistance assay, AmpliSensSexually transmitted infections · 2023Article
- Galacto-Oligosaccharides as an Anti-Infective and Anti-Microbial Agent for Macrolide-Resistant and -SensitivePathogens (Basel, Switzerland) · 2023Article
- Retrospective and Comparative Study of Three Molecular Assays for the Macrolide Resistance Detection inInternational journal of molecular sciences · 2023Article
- Novel mechanisms of macrolide resistance revealed byFrontiers in cellular and infection microbiology · 2023Article
- Global research trends ofFrontiers in pediatrics · 2023Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrolide-resistant mutants of Mycoplasma pneumoniae were selected in vitro from the susceptible reference strain M129, by 23 to 50 serial passages in subinhibitory concentrations of macrolides and related antibiotics, erythromycin A, azithromycin, josamycin, clindamycin, quinupristin, quinupristin-dalfopristin, pristinamycin, and telithromycin. Mutants for which the MICs are increased could be selected with all antibiotics except the streptogramin B quinupristin. Portions of genes encoding 23S rRNA (domains II and V) and ribosomal proteins L4 and L22 of mutants were amplified by PCR, and their nucleotide sequences were compared to those of the susceptible strain M129. No mutation could be detected in domain II of 23S rRNA. Two point mutations in domain V of 23S rRNA, C2611A and A2062G, were selected in the presence of erythromycin A, azithromycin, josamycin, quinupristin-dalfopristin, and telithromycin. Mutants selected in the presence of clindamycin and telithromycin harbored a single amino acid change (H70R or H70L, respectively) in ribosomal protein L4, whereas insertions of one, two, or three adjacent glycines at position 60 (M. pneumoniae numbering) were selected in the presence of both streptogramin combinations. Telithromycin was the sole antibiotic that selected for substitutions (P112R and A114T) and deletions ((111)IPRA(114)) in ribosomal protein L22. Three sequential mutational events in 23S rRNA and in both ribosomal proteins were required to categorize the strain as resistant to the ketolide. Azithromycin and erythromycin A were the only selector antibiotics that remained active (MICs, 0.06 and 1 micro g/ml, respectively) on their mutants selected after 50 passages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.